At the Rotterdam site of the European Randomized Study of Screening for Prostate Carcinomas about 9600 men between 54 and 76 years old have been randomized, of which 50% for screening by prostate-specific antigen (PSA), digital rectal examination (DRE), and transrectal ultrasonography up to March 1996.
The detection rate of cancer is 4.3%, and the overall number of biopsies per cancer is 5.1. By clinical staging 91% of cancers are organ-confined (T2c or less) ; by pathologic staging after radical prostatectomy 56% are confined.
The best sole predictor of a positive biopsy is total serum PSA, followed by DRE.
In the intermediate PSA range between 4 and 10 ng/mL the free to total PSA ratio of 0.20 can reduce significantly the number of false-positive biopsy indications by 38% at a loss of 12% of undetected carcinomas.
Mots-clés Pascal : Adénocarcinome, Prostate, Marqueur tumoral, Antigène spécifique prostate, Dépistage, Intérêt, Sensibilité, Norme, Résultat, Homme, Pays Bas, Europe, Tumeur maligne, Appareil urinaire pathologie, Appareil génital mâle pathologie, Prostate pathologie, Biologie
Mots-clés Pascal anglais : Adenocarcinoma, Prostate, Tumoral marker, Prostate specific antigen, Medical screening, Interest, Sensitivity, Standards, Result, Human, Netherlands, Europe, Malignant tumor, Urinary system disease, Male genital diseases, Prostate disease, Biology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0288591
Code Inist : 002B14D02. Création : 15/07/1997.